CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

This high-yield stock has raised its dividend for 27 consecutive years and is well-positioned to maintain the growth streak.

Five years ago this month, in November 2020, medical history was made at Richmond Pharmacology when a patient received the ...

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.